Related Experiment Videos
[Autonomic dysfunction in children with traumatic brain injury].
N Rodríguez1, A Febrer, M Meléndez
1Servicio de Rehabilitación y Medicina Física, Hospital Universatari Sant Joan de Déu, 08950 Esplugues de Llobregat, Barcelona, Spain. nrodriguez@hsjdbcn.org
Revista De Neurologia
|July 28, 2006
Summary
Autonomic dysfunction following traumatic brain injury presents management challenges. Oral baclofen and midazolam showed effectiveness in two pediatric cases, highlighting potential therapeutic options.
Area of Science:
- Neuroscience
- Pediatric Neurology
- Critical Care Medicine
Background:
- Autonomic dysfunction syndrome (ADS) post-traumatic brain injury (TBI) involves central adrenergic hyperactivity.
- Management is challenging due to lack of standardized treatments and unclear etiology.
Observation:
- Two pediatric patients with severe TBI experienced hypertension, tachycardia, sweating, and spasticity.
- Symptoms persisted through coma and awakening, complicating diagnosis and treatment.
Findings:
- Oral baclofen and midazolam appeared most effective in managing severe autonomic dysfunction symptoms in these cases.
- Initial differential diagnoses included sepsis, withdrawal syndromes, and epilepsy.
Implications:
- Effective treatment of ADS is crucial for minimizing secondary injury and functional worsening in pediatric TBI survivors.
- Further research into the pathophysiology and standardized treatment protocols for pediatric post-TBI autonomic dysfunction is warranted.